MHY 908, with the CAS number 1393371-39-5, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is characterized by its specific molecular structure, which includes various functional groups that contribute to its biological activity. The compound is often studied for its role as a selective inhibitor, potentially impacting certain biochemical pathways. Its solubility, stability, and reactivity are influenced by its molecular configuration, making it suitable for various experimental conditions. Additionally, MHY 908 may exhibit specific pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, which are critical for evaluating its efficacy and safety in biological systems. Research into this compound is ongoing, focusing on its mechanisms of action and potential applications in treating diseases. As with any chemical substance, proper handling and safety protocols are essential when working with MHY 908 in laboratory settings.

MHY908 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ that increases transcriptional activity of PPARα and PPARγ in a luciferase reporter assay in AC2F rat liver cells when used at a concentration of 5 μM.
In vivo
, MHY908 (3 mg/kg per day) reduces serum glucose, triglyceride, and insulin levels and improves hepatic steatosis by reducing hepatic triglyceride levels and lipid droplet accumulation in
db/db
mice and 20-month-old rats. It reduces peroxynitrite and COX-2 levels, reactive oxygen species (ROS) production, and Akt phosphorylation in isolated kidney from 20-month-old rats when administered at a dose of 3 mg/kg. MHY908 inhibits mushroom tyrosinase (IC
50
= 8.19 μM). It also inhibits increases in melanin content in α-melanocyte stimulating hormone-induced B16/F10 murine melanoma cells when used at a concentration of 10 μM.

MHY 908

1393371-39-5: MHY 908, with the CAS number 1393371-39-5, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is characterized by its specific molecular structure, which includes various functional groups that contribute to its biological activity. The compound is often studied for its role as a selective inhibitor, potentially impacting certain biochemical pathways. Its solubility, stability, and reactivity are influenced by its molecular configuration, making it suitable for various experimental conditions. Additionally, MHY 908 may exhibit specific pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, which are critical for evaluating its efficacy and safety in biological systems. Research into this compound is ongoing, focusing on its mechanisms of action and potential applications in treating diseases. As with any chemical substance, proper handling and safety protocols are essential when working with MHY 908 in laboratory settings.

<p>MHY908 is a fatty acid that has been shown to inhibit tyrosinase activity. This inhibition leads to decreased melanogenesis and reduced hepatic steatosis in rats. MHY908 also has the ability to increase glucose uptake in liver cells, which may be due to its anti-inflammatory properties. The anti-inflammatory properties of MHY908 have been shown to be reactive oxygen species (ROS)-dependent, as ROS production is necessary for MHY908-induced insulin resistance. MHY908 also has neuroprotective effects on rat kidneys and protects against oxidative stress induced by ROS.</p>

MHY908

<p>MHY908, a novel inhibitor of melanogenesis, potently inhibits mushroom tyrosinase activity in a dose-dependent manner.</p>

CAS 1393371-39-5

MHY 908

MHY908

Ref: 3D-TFC37139

MHY908

Ref: TM-T28035